Gennifer E. Merrihew

Gennifer E. Merrihew

Auto-generated profile, based on publicly available information

Gennifer E. Merrihew

University of Washington

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2019 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Open access
DADario Amodei
Dario Amodei
JEJarrett Egertson
Jarrett Egertson
BMBrendan X. MacLean
Brendan X. MacLean
RJRichard Johnson
Richard Johnson
GMGennifer E. Merrihew
Gennifer E. Merrihew
MMMichael J. MacCoss
Michael J. MacCoss
A major goal of proteomics research is the accurate and sensitive identification and quantification of a broad range of proteins within a sample. Data-independent acquisition (DIA) approaches that ...

1 April 2019 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
MCMatthew D. Campbell
Matthew D. Campbell
JDJicheng Duan
Jicheng Duan
ASAshton T. Samuelson
Ashton T. Samuelson
MGMatthew J. Gaffrey
Matthew J. Gaffrey
GMGennifer E. Merrihew
Gennifer E. Merrihew
David J. MarcinekDavid J. Marcinek
David J. Marcinek

11 June 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
HLHaiming Liu
Haiming Liu
KKKora Krumm
Kora Krumm
BABarbara Anderson
Barbara Anderson
ACAnthony Christiani
Anthony Christiani
LSLena Strait
Lena Strait
JGJose Garcia
Jose Garcia
Our study was to characterize sarcopenia in C57BL/6J mice using a clinically relevant definition to investigate the underlying molecular mechanisms. Aged male (23–32 months old) and female (27–28 months old) C57BL/6J mice were classified as non-, probable-, or sarcopenic based on assessments of grip strength, muscle mass, and treadmill running time, using 2 SDs below the mean of their young counterparts as cutoff points. A 9%–22% prevalence of sarcopenia was identified in 23–26 month-old male mice, with more severe age-related declines in muscle function than mass. Females aged 27–28 months showed fewer sarcopenic but more probable cases compared with the males. As sarcopenia progressed, a decrease in muscle contractility and a trend toward lower type IIB fiber size were observed in males. Mitochondrial biogenesis, oxidative capacity, and AMPK-autophagy signaling decreased as sarcopenia progressed in males, with pathways linked to mitochondrial metabolism positively correlated with muscle mass. No age- or sarcopenia-related changes were observed in mitochondrial biogenesis, OXPHOS complexes, AMPK signaling, mitophagy, or atrogenes in females. Our results highlight the different trajectories of age-related declines in muscle mass and function, providing insights into sex-dependent molecular changes associated with sarcopenia progression, which may inform the future development of novel therapeutic interventions.

5 November 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
JHJonathan J. Herrera
Jonathan J. Herrera
SLSean Louzon
Sean Louzon
KPKaitlyn Pifer
Kaitlyn Pifer
DLDanielle Leander
Danielle Leander
GMGennifer E. Merrihew
Gennifer E. Merrihew
MGMichael Garratt
Michael Garratt
With an expanding aging population burdened with comorbidities, there is considerable interest in treatments that optimize health in later life. Acarbose (ACA), a drug used clinically to treat type 2 diabetes mellitus (T2DM), can extend mouse life span with greater effect in males than in females. Using a genetically heterogeneous mouse model, we tested the ability of ACA to ameliorate functional, pathological, and biochemical changes that occur during aging, and we determined which of the effects of age and drug were sex dependent. In both sexes, ACA prevented age-dependent loss of body mass, in addition to improving balance/coordination on an accelerating rotarod, rotarod endurance, and grip strength test. Age-related cardiac hypertrophy was seen only in male mice, and this male-specific aging effect was attenuated by ACA. ACA-sensitive cardiac changes were associated with reduced activation of cardiac growth–promoting pathways and increased abundance of peroxisomal proteins involved in lipid metabolism. ACA further ameliorated age-associated changes in cardiac lipid species, particularly lysophospholipids — changes that have previously been associated with aging, cardiac dysfunction, and cardiovascular disease in humans. In the liver, ACA had pronounced effects on lipid handling in both sexes, reducing hepatic lipidosis during aging and shifting the liver lipidome in adulthood, particularly favoring reduced triglyceride (TAG) accumulation. Our results demonstrate that ACA, already in clinical use for T2DM, has broad-ranging antiaging effects in multiple tissues, and it may have the potential to increase physical function and alter lipid biology to preserve or improve health at older ages.

23 November 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
JRJoshua C. Russell
Joshua C. Russell
GMGennifer E. Merrihew
Gennifer E. Merrihew
JRJulia E. Robbins
Julia E. Robbins
NPNadia Postupna
Nadia Postupna
TKTyek-Kyun Kim
Tyek-Kyun Kim
MKMatt Kaeberlein
Matt Kaeberlein
Cells from bacteria to human release vesicles into their extracellular environment. These extracellular vesicles (EVs) contain multiple classesof molecules, including nucleic acids, proteins, and lipids. The isolation and analysis of EV cargos from mammalian cell culture and liquid biopsysamples has become a powerful approach for uncovering the messages that are packaged into these organelles. However, this approach has not been tenable in invertebrate model systems due to lack of sufficient amounts of pure EVs. Here we report a robust and reproducible procedure to isolateEVs from Caenorhabditis elegans with yields similar to those obtained from human cell culture. Through nanoparticle tracking, transmission electron microscopy, flow cytometry, mass spectrometry, RNAseq, and immunoaffinity analysis we provide the first ever detailed characterization of C. elegans EV composition and demonstrate that C. elegans EVs share fundamentally similar properties with their mammalian counterparts. These include vesicle size, enrichment for lipid rafts, and similar types of RNA and protein cargos. This ability of isolate pure EVs on ascale amenable to multiple types of downstream analyses permits, multi-omics characterization of EV cargos in an invertebrate model system.

2 January 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
YCYing Ann Chiao
Ying Ann Chiao
HZHuiliang Zhang
Huiliang Zhang
MSMariya Sweetwyne
Mariya Sweetwyne
JWJeremy Whitson
Jeremy Whitson
YTYing Sonia Ting
Ying Sonia Ting
PRPeter Rabinovitch
Peter Rabinovitch
Diastolic dysfunction is a prominent feature of cardiac aging in both mice and humans. We show here that 8-week treatment of old mice with the mitochondrial targeted peptide SS-31 (elamipretide) can substantially reverse this deficit. SS-31 normalized the increase in proton leak and reduced mitochondrial ROS in cardiomyocytes from old mice, accompanied by reduced protein oxidation and a shift towards a more reduced protein thiol redox state in old hearts. Improved diastolic function was concordant with increased phosphorylation of cMyBP-C Ser282 but was independent of titin isoform shift. Late-life viral expression of mitochondrial-targeted catalase (mCAT) produced similar functional benefits in old mice and SS-31 did not improve cardiac function of old mCAT mice, implicating normalizing mitochondrial oxidative stress as an overlapping mechanism. These results demonstrate that pre-existing cardiac aging phenotypes can be reversed by targeting mitochondrial dysfunction and implicate mitochondrial energetics and redox signaling as therapeutic targets for cardiac aging.